Proteomic Testing

This test quantitatively Analyzes 7000 Proteins

A.) 4-Year Heart Attack, Stoke and heart Failure Risk Determination

  • Quantitative analysis, coupled with proteomic modeling of at least 27 circulating proteins associated with pathogenesis of cardiovascular diseases, predicts the absolute likelihood of myocardial infarction, stroke, hospitalization for heart failure, and all-cause death within 4 years.

  • 14 of the proteins tested are positively correlated with risk, and 13 are negatively correlated. Average contribution of each protein ranged from 1 to 23%.

  • The method was tested with a cohort of 11,609 individuals in the U.S. The findings were subsequently replicated in a Japanese cohort. This test stratifies patients into 4 risk categories.

  • Only about half of the patients in the high risk group are associated with event-free survival after 4 years.

The test also determines second heart attack risk, and VO2Max, a cardiac mortality predictor.

B.) 5-Year Lung Cancer Risk Determination

  • This test determines 5-year lung cancer risk.

  • After combining with lifestyle risk factors such as smoking, and polygenic risks of lung cancer specific to Asians, the predictive power of a comprehensive lung cancer risk determination may be improved.

c) 5-Year and 20-Year Dementia Risk Determination

  • This test determines 20-year dementia risk. For patients 65 years and older, the 5-year risk can be determined.

  • After combining with polygenic risks of dementia and multiple neuro-degenerative disorders, and monogenic risk factors such as those conferred by APOE mutations, the predictive power of a comprehensive dementia risk determination may be improved.

d) determine Fatty Liver, Visceral fat (fat around internal organs) and Impaired Glucose Tolerance.

  • This test also determine multiple risk factors that can increase the risk of cardiometabolic disorders.

E) Determine Chronic Kidney Disease

  • With fatty liver, visceral fat and impaired glucose tolerance, the test inform comprehensive risk for prediabetics.

F) Determine Cardiorespiratory indicator, VO2Max, an Mortality indicator of Pre-mature death in Adults.

Test Process

  • All sample must be stored at -80C within one hour. We have established a low-temperature sample handling process to manage patient samples.

  • For patient, convenient blood draw at physician office. Our specialist (PhD Scientist will collect blood sample at the same time).

  • The test is performed at a U.S. CLIA-certified and CAP-accredited laboratory.

  • Clinical report is issued by a board-certified medical director (Dual M.D. & PhD. holder).